Indeed.
I liked two things about it:
1) How fast it accelerated, sales trajectory was steep when it started from zero sales, yes the real big sales took some years to hit, but even the first 4 to 5 years were incredible.
2) The high market penetration and how big it became despite the safety issues and warnings later on. This is what happens when there is not much out there in terms therapeutics, there is nothing for OA at all, just temporary pain relief and even thats not too safe and causes other problems.
DYOR
iPPS and the not so Looney comparison, page-49
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $73.55M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 22.0¢ | 20.5¢ | $264.9K | 1.250M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 47501 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.0¢ | 4460 | 1 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |